Johnson & Johnson (JNJ) Stock Analysis

Latest ClaritX AI analysis ·

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

MetricValue
Price$285.75
Market cap$687.9B
SectorHealthcare
IndustryDrug Manufacturers - General
ClaritX AI score68/100
Price/Book8.58
Dividend yield1.85%
Beta0.23

AI verdict

Johnson & Johnson continues to operate as an elite defensive anchor, highlighted by its exceptionally low beta of 0.235, which insulates the stock from broader market volatility and aggressive tech-sector rotations. Fueled by a robust 7.7% growth rate in its Innovative Medicine division and the psychological relief of quantifying its talc liabilities via a $5.5 billion Q3 charge, the stock has surged over 10% since mid-October. Consequently, JNJ is now trading at $285.75, sitting precariously close to its 52-week high of $288.11. This momentum is corroborated by a borderline-overbought RSI of 69.88. While buying a stock near its absolute peak reflects strong institutional conviction, it inherently elevates the risk of short-term pullbacks, especially given that the company's MedTech division is lagging with a mere 2.5% growth rate. From a fundamental and valuation standpoint, the stock appears fully priced. JNJ has met the average analyst price target of $285.67, and insiders are actively locking in profits at these levels. Nevertheless, the company’s Dividend King status remains unimpeachable; a healthy free cash flow of $8.41 per share easily covers the 1.85% dividend yield. Ultimately, JNJ is a premier, sleep-well-at-night holding for existing long-term investors focused on capital preservation and compounding income. However, for new capital looking for outsized returns, the lack of immediate upside at this 52-week high valuation warrants a cautious, neutral stance. Rati

What this score has been worth

ClaritX scores JNJ 68 out of 100 (snapshot 2026-11-20).

Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 206 analyses that scored in the 50-69 band, the average forward return was -8.7% with a 40% win rate, -1.8pp against the S&P 500. That is a measured tendency across many names, not a forecast for JNJ — roughly 60% of stocks in this band still lost money.

The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.

Run a fresh 9-perspective AI analysis of JNJ — free

Browse all stocks · AI Stock Rankings · AI Track Record